1q2d Citations

Molecular basis for Gcn5/PCAF histone acetyltransferase selectivity for histone and nonhistone substrates.

Biochemistry 42 14366-74 (2003)
Cited: 54 times
EuropePMC logo PMID: 14661947

Abstract

Histone acetyltransferase (HAT) proteins often exhibit a high degree of specificity for lysine-bearing protein substrates. We have previously reported on the structure of the Tetrahymena Gcn5 HAT protein (tGcn5) bound to its preferred histone H3 substrate, revealing the mode of substrate binding by the Gcn5/PCAF family of HAT proteins. Interestingly, the Gcn5/PCAF HAT family has a remarkable ability to acetylate lysine residues within diverse cognate sites such as those found around lysines 14, 8, and 320 of histones H3, H4, and p53, respectively. To investigate the molecular basis for this, we now report on the crystal structures of tGcn5 bound to 19-residue histone H4 and p53 peptides. A comparison of these structures with tGcn5 bound to histone H3 reveals that the Gcn5/PCAF HATs can accommodate divergent substrates by utilizing analogous interactions with the lysine target and two C-terminal residues with a related chemical nature, suggesting that these interactions play a general role in Gcn5/PCAF substrate binding selectivity. In contrast, while the histone H3 complex shows extensive interactions with tGcn5 and peptide residues N-terminal to the target lysine, the corresponding residues in histone H4 and p53 are disordered, suggesting that the N-terminal substrate region plays an important role in the enhanced affinity of the Gcn5/PCAF HAT proteins for histone H3. Together, these studies provide a framework for understanding the substrate selectivity of HAT proteins.

Reviews - 1q2d mentioned but not cited (3)

  1. Classification of intrinsically disordered regions and proteins. van der Lee R, Buljan M, Lang B, Weatheritt RJ, Daughdrill GW, Dunker AK, Fuxreiter M, Gough J, Gsponer J, Jones DT, Kim PM, Kriwacki RW, Oldfield CJ, Pappu RV, Tompa P, Uversky VN, Wright PE, Babu MM. Chem Rev 114 6589-6631 (2014)
  2. Understanding protein non-folding. Uversky VN, Dunker AK. Biochim Biophys Acta 1804 1231-1264 (2010)
  3. Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. Uversky VN. Expert Rev Proteomics 7 543-564 (2010)

Articles - 1q2d mentioned but not cited (4)



Reviews citing this publication (10)

  1. Histone acetyltransferase complexes: one size doesn't fit all. Lee KK, Workman JL. Nat Rev Mol Cell Biol 8 284-295 (2007)
  2. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Marmorstein R, Zhou MM. Cold Spring Harb Perspect Biol 6 a018762 (2014)
  3. Catalysis and substrate selection by histone/protein lysine acetyltransferases. Berndsen CE, Denu JM. Curr Opin Struct Biol 18 682-689 (2008)
  4. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Hodawadekar SC, Marmorstein R. Oncogene 26 5528-5540 (2007)
  5. Histone-modifying enzymes: encrypting an enigmatic epigenetic code. Couture JF, Trievel RC. Curr Opin Struct Biol 16 753-760 (2006)
  6. Histone modification enzymes: novel targets for cancer drugs. Kristeleit R, Stimson L, Workman P, Aherne W. Expert Opin Emerg Drugs 9 135-154 (2004)
  7. Histone acetyltransferases: Rising ancient counterparts to protein kinases. Yuan H, Marmorstein R. Biopolymers 99 98-111 (2013)
  8. Lysine acetyltransferase inhibitors: structure-activity relationships and potential therapeutic implications. Fiorentino F, Mai A, Rotili D. Future Med Chem 10 1067-1091 (2018)
  9. The Biological Significance of Targeting Acetylation-Mediated Gene Regulation for Designing New Mechanistic Tools and Potential Therapeutics. O'Garro C, Igbineweka L, Ali Z, Mezei M, Mujtaba S. Biomolecules 11 455 (2021)
  10. Alzheimer's Disease-Related Epigenetic Changes: Novel Therapeutic Targets. Paniri A, Hosseini MM, Akhavan-Niaki H. Mol Neurobiol (2023)

Articles citing this publication (37)